Tesamorelin

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Tesamorelin
Clinical data
Trade names Egrifta
AHFS/Drugs.com Multum Consumer Information
MedlinePlus a611035
Legal status
Routes Subcutaneous injection
Pharmacokinetic data
Metabolism Proteolysis
Half-life 38 minutes
Excretion Renal/proteolysis
Identifiers
CAS number 901758-09-6 YesY
ATC code H01AC06
PubChem CID 16137828
UNII MQG94M5EEO YesY
KEGG D09015 YesY
Chemical data
Formula C221H366N72O67S 
Molecular mass 5135.86 g/mol

Tesamorelin (trade name Egrifta) is a synthetic form of growth-hormone-releasing hormone (GHRH) which is used in the treatment of HIV-associated lipodystrophy. Tesamorelin is produced and developed by Theratechnologies, Inc. of Canada.

Tesamorelin is a synthetic peptide consisting of all 44 amino acids of human GHRH with the addition of a trans-3-hexenoic acid group.[1]

See also[edit]

References[edit]